Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396455 | 0.84 | KMT2A (0.50) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL953947 | 0.84 | KMT2A (0.50) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL958241 | 0.84 | KMT2A (0.50) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL963408 | 0.84 | MEN1 (0.46) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL14044375 | 0.84 | CYP2D6 (0.46) | MEN1LMNACYP2D6HRH1SCN1A | |
| Bromide SCHEMBL4505514 | 0.83 | KMT2A (0.49) | MEN1LMNACYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL10869034 | 0.83 | KMT2A (0.49) | MEN1LMNACYP2D6HRH1SCN1A | |
| Bromide SCHEMBL4505510 | 0.83 | KMT2A (0.49) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL5657376 | 0.80 | MEN1 (0.43) | MEN1LMNACYP2D6HRH1SCN1A | |
| Maleic Acid SCHEMBL10360499 | 0.79 | HRH1 (0.44) | MEN1LMNACYP2D6HRH1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638639-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7557126-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351718-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351717-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-01 | — | — | US | disclosed |
| US-7250414-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-7208515-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-04-05 | — | — | US | disclosed |
| US-7183292-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | MEN1 1247/4885LMNA 3786/4885CYP2D6 483/4885 |
| US-20070032524-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM5 | MEN1 1591/4885LMNA 2237/4885CYP2D6 519/4885 |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | MEN1 1247/4885LMNA 3786/4885CYP2D6 483/4885 |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | MEN1 1011/4885LMNA 1646/4885CYP2D6 456/4885 |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | MEN1 1247/4885LMNA 3786/4885CYP2D6 483/4885 |
| US-20070078163-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | MEN1 1247/4885LMNA 3786/4885CYP2D6 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.